Role of prebiotic oligosaccharides in prevention of gastrointestinal infections;Revisión del papel de los oligosacáridos prebióticos en la prevención de infecciones gastrointestinales

Archivos Latinoamericanos de Nutricion

Volumn 59, Issue 4, 2009, Pages 358-368

  Domínguez Vergara, Ana María ^a   Vázquez Moreno, Luz ^a   Montfort, Gabriela Ramos Clamont ^a  

^a González Méndez are with Laboratorio de Investigacion en Carne y Productos Carnicos   (Mexico)

Author keywords

Fructooligosaccharides; Galactooligosaccharides; Infections; Insulin; Prebiotic oligosaccharides

Indexed keywords

OLIGOSACCHARIDE; PREBIOTIC AGENT; CARBOHYDRATE DIET;

ANIMAL; BACTERIAL INFECTION; BREAST FEEDING; CARBOHYDRATE DIET; DIARRHEA; GASTROINTESTINAL DISEASE; HUMAN; INTESTINE; MICROBIOLOGY; NEWBORN; REVIEW; ADMINISTRATION AND DOSAGE; BACTERIAL INFECTIONS; GASTROINTESTINAL DISEASES;

ANIMALS; BACTERIAL INFECTIONS; BREAST FEEDING; DIARRHEA; DIETARY CARBOHYDRATES; GASTROINTESTINAL DISEASES; HUMANS; INFANT, NEWBORN; INTESTINES; OLIGOSACCHARIDES; PREBIOTICS;

ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 77953067618     PISSN: 00040622     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Fric P. Probiotics and prebiotics renaissance of a therapeutic principle. Cen Eur J Med 2007; 2(3):237-270.
2. Berg RD. The indigenous gastrointestinal microflora. Trends in Microbiol 1996; 4:430-435.
3. Blaut M, Clavel T. Metabolic diversity of the intestinal microbiota: implications for health and disease J Nutr 2007; 137: S751-S755.
4. Swidsinski A, LadhoffA, Pemthaler A, Swidsinski S, Loening-Baucke V, Ortner M, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122:44-54.
5. Collins MD, Gibson GR. Probiotics, prebiotics, and symbiotics: approaches for modulating the microbial ecology of the gut. Am J Clin Nutr 1999; 69:S1052-S1057.
6. Gibson GR. Dietary modulation of the human gut microflora using the prebiotics oligofructose and inulin. J Nutr 1999; 129(7):S1438-S1441.
7. Macfarlane GT, Steed H, Macfarlane S. Bacterial metabolism and health-related effects of galacto-oligosaccharides and other prebiotics. J Appl Microbiol 2007; 1:40-47.
8. Guarner F. Studies with inulin-type fructans on intestinal infections, permeability, and inflammation. J Nutr 2007; 137:S2568-S2571.
9. Wilks M. Bacteria and early human development. Early Hum Dev 2007; 83:165-170.
10. Nicholson JK, Holmes E, Wilson ID. Gut microorganisms, mammalian metabolism and personalized health care. Nature Rev Microbiol 2005; 3: 1-8.
11. Cummings JH, Stephen AM. Carbohydrate terminology and classification. Eur J Clin Nutr 2007; 61:S5-S18.
12. Gibson GR, Probert HM, van Loo J, Rastall RA, Roberfroid M. Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutr Res Rev 2004; 17:259-275.
13. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995; 125:1401-1412.
14. Bouhnik Y, Raskine L, Simoneau G, Vicaut E, Neut C, Flourie, et al. The capacity of nondigestible carbohydrates to stimulate fecal bifidobacteria in healthy humans: a double-blind, randomized, placebo-controlled, parallel-group, dose-response relation study. Am J Clin Nutr 2004; 80:1658-1664.
15. Gibson GR, Beatty ER, Wang X, Cummings JH. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterol, 1995; 108:975-982.
16. Forchielli ML. Walker WA. The effect of protective nutrients on mucosal defense in the immature intestine. Acta Paediatr 2005; 94:74-83.
17. Cummings JH, Englyst H. Fermentation in the human large intestine and the available substrates. Am J Clin Nutr. 1987; 45:1243-1255.
18. Marcil V, Delvin E, Seidman E, Poitras L, Zoltowska M, Garofalo C, et al. Modulation of lipid synthesis, apolipoprotein biogenesis and lipoprotein assembly by butyrate. Am J Physiol Gastrointest Liver Physiol .2002; 283:G340-G346, .
19. Emenaker NJ, CalafGM, Cox D, Basson MD, Qureshi N. Short-chain fatty acids inhibit invasive human colon cancer by modulating uPA, TIMP-1, TIMP-2, Mutant p53, Bcl-2, Bax, p21 and PCNA protein expression in an in Vitro cell culture model. J Nutr 2001; 131:S3041-S3046.
20. Isolauri E, Salminen S, Ouwehand AC. Microbial-gut interactions in health and disease. Probiotics. Best Pract Res Clin Gastroenterol 2004; 18(2): 299-313.
21. Stahl B, Thurl S, Zeng J, Karas M, Hillenkamp F, Steup M, et al. Oligosaccharides from milk as revealed by matrix-assisted laser desorption/ionization mass spectrometry. Anal Biochem 1994; 223:218-226. (Pubitemid 24368970)
22. Boehm G, Stahl B. Oligosaccharides from milk. J Nutr 2007; 3:S847-S849.
23. Kunz C, Rudloff S, Baier W, Klein N, Strobel, S. Oligosac-charides in human milk: structural, functional, and metabolic aspects. Ann Rev Nutr 2000; 20:699-722.
24. Dai D, Walker WA. Protective nutrients and bacterial colonization in the immature human gut. Adv Pediatr 1999; 46:353-382.
25. Manning TS, Gibson R. Prebiotics. Best Pract Res Clin Gastroenterol 2004; 18(2):287-98.
26. Engfer MB, Stahl B, Finke B, Sawatzki G, Daniel H. Human milk oligosaccharides are resistant to enzymatic hydrolysis in the upper gastrointestinal tract. Am J Clin Nutr 2000;71:1589-1596.
27. Gnoth MJ, Kunz C, Kinne-Saffran E, Rudloff S. Human milk oligosaccharides are minimally digested in vitro. Jf Nutr 2000; 130:3014-3020.
28. Petschow BW, Talbott RD. Growth promotion of Bifidobacterium species by whey and casein fractions from human and bovine milk. J Clin Microbiol 1990; 28:287-292.
29. Coppa GV, Bruni S, Morelli L, Soldi S, Gabrielli O. The first prebiotics in humans: Human milk oligosaccharides. J Clin Gastroenterol 2004; 38(6 Suppl):S80-83.
30. Bode L, Kunz C, Muhly-Reinholz M, Mayer K, Seeger W, Rudloff S. Inhibition of monocyte, lymphocyte, and neutro-phil adhesion to endothelial cells by human milk oligosaccha-rides. Thromb Haemost 2004; 92:1402-1410.
31. Bode L, Rudloff S, Kunz C, Strobel S, Klein N. Human milk oligosaccharides reduce platelet-neutrophil complex formation leading to a decrease in neutrophil X2 integrin expression. J Leukocyte Biol 2004; 76:1-7.
32. Kannagi R. Regulatory roles of carbohydrate ligands for selectins in the homing of lymphocytes. Curr Opin Struc Biol 2002; 12:599-608.
33. Penders J, Thijs C, Vink C, et al. Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics 2006; 118(2):511-521.
34. Dicksved J, Floistrup H, Bergstrom A, et al. Molecular fingerprinting of the fecal microbiota of children raised according to different lifestyles. Appl Environ Microbiol 2007; 73(7):2284-2289.
35. Mitsuoka T. Intestinal flora and aging. Nutr Rev 1992; 50(12):438-446.
36. Sartor R, Muehlbauer M. Microbial host interactions in IBD: implications for pathogenesis and therapy. Curr Gastroenterol Rep 2007; 9:497-507.
37. Lindsay JO, Whelan K, Stagg AJ, Gobin P, Al-Hassi HO, Rayment N, et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharides in patients with Crohn's disease. Gut 2006; 55:348-355.
38. Moreau NM, Martin LJ, Toquet CS, Laboisse CL, Nguyen PG, Siliart, BS, et al. Restoration of the integrity of rat caeco-colonic mucosa by resistant starch, but not by fructo-oligosac-charides, in dextran sulphate sodium-induced experimental colitis. British J Nutri. 2003. 90:75-85.
39. Delzenne NM. Oligosaccharides: state of the art. Proc Nutr Soc 2003; 62:177-182.
40. Roberfroid M. Prebiotic: The concept revisited. J Nutr 2007; 137:S830-S837.
41. Macfarlane S, Macfarlane GT, Cummings JH. Prebiotics in the gastrointestinal tract. Alim Pharm Ther 2006; 24:701-714.
42. Tuohy KM, Ziemer CJ, Klinder A, Knobel Y, Pool-Zobel BL, Gibson GR. A human volunteer study to determine the prebiotic effects of lactulose powder on human colonic microbiota. Microb Ecol Health Dis 2002; 14: 165-173.
43. Playne MJ, Crittenden RG. Commercially available oligosaccharides. Bull Int Dairy Fed 1996; 313:10-22.
44. Crittenden RG, Playne MJ. Production, properties and applications of food grade oligosaccharides. Trends Food Sci Technol 1994; 7:353-361.
45. Biedrzycka E, Bielecka M. Effectiveness of fructans of different degrees of polymerization. Trends Food Sci Technol 2004; 15:170-175.
46. Gibson GR. Prebiotics as gut microflora management tools. J Clin Gastroenterol. 2008; 42:S75-S79.
47. Haarman M, Knol J. Quantitative real-time PCR assays to identify and quantify fecal Bifidobacterium species in infants receiving a prebiotic infant formula. Appl Enviro Microbio. 2005; 71(5):2318-24.
48. Rycroft CE, Jones MR, Gibson GR Rastall RA. A comparative in vitro evaluation of the fermentation properties of prebi-otic oligosaccharides. J Appl Microbiol 2001; 91(5):878-887.
49. Boehm G, Jelinek J, Stahl B, van Laere, K, Knol J, Fanaro, S. Prebiotics in infant formulas. J Clin Gastroenterol 2004; 38:S76-S79.
50. Casburn-Jones AC, Farthing MJ. Management of infectious diarrhea. Gut 2004; 53:296-305.
51. Black RE, Morris SS, Bryce J. Where and why are 10 million children dying every year? Lancet 2003; 361:2226-2234.
52. Vandenplas Y, Salvatore S, Viera M, Devreker T, Hauser B. Probiotics in infectious diarrhea in children: are they indicated. Eur J Pediatr 2007; 166:211-1218.
53. Kunz C, Rudloff, S. Potential anti-inflammatory and anti-infectious effects of human milk oligosaccharides. Adv Exp Med Biol 2008; 606:455-465.
54. Kunz C, Rudloff S. Health promoting aspects of milk oligosaccharides. Int Dairy J 2006; 16(11):1341-1346.
55. Jones G, Steketee RW, Black RE, Bhutta Z, Morris S. How many child deaths can we prevent this year? Lancet 2003; 362:65-71.
56. Hamosh M. Bioactive factors in human milk. Pediatr Clin North Am 2001; 48:69-86.
57. Morrow AL, Rangel JM. Human milk protection against infectious diarrhea: implications for prevention and clinical care seminars in pediatric infectious diseases. Sem Pediatr Infect Dis. 2004; 15:221-228.
58. Cleary TG. Human milk protective mechanisms. Adv Exp Med Biol 2004; 554:145-154.
59. Wang B, Brand-Miller J. The role and potential of sialic acid in human nutrition. Eur J Clin Nutr 2003; 57:1351-1369.
60. Fanaro S, Vigi V. Which role for prebiotics at weaning? J Clin Gastroenterol 2008; 42:S209-S213.
61. Heithoff DM, Conner CP, Mahan MJ. Dissecting the biology of a pathogen during infection. Trends Microbiol 1997; 12:509-513.
62. Sharon N. Carbohydrates as future anti-adhesion drugs for infectious diseases. Bioch Bioph Acta 2006; 1760(4):527-537.
63. Ofek I, Sharon N. Adhesins as lectins: specificity and role in infection. Curr Top Microbiol Immunol 1990; 151:91-113.
64. Martin-Sosa S, Martin MJ, Hueso P. The sialylated fraction of milk oligosaccharides is partially responsible for binding to enterotoxigenic and uropathogenic Escherichia coli human strains. J Nutr. 2002; 132(10): 3067-3072.
65. Crane JK, Azar S, Stam A, Newburg D. Oligosaccharides from human milk block binding and activity of the Escherichia coli heat-stable enterotoxin (STa) in T84 intestinal cells. J Nutr 1994; 12:2358-2364.
66. Bode L. Recent advances on structure, metabolism and func- tion of human milk oligosaccharides. J Nutr 2006; 136:2127-30.
67. Ten Bruggencate SJ, Bovee-Oudenhoven IM, Lettink-Wissink M, Van der Meer R. Dietary fructo-oligosaccharides dose-dependently increase translocation of salmonella in rats. J Nutr 2003; 133(7):2313-2318.
68. Buddington KK, Donahoo JB, Buddington RK. Dietary oligofructose and inulin protect mice from enteric and systemic pathogens and tumor inducers. J Nutr 2002; 132:472-477.
69. Lewis S, Burmeister S, Brazier J. Effect of the prebiotic oligofructose on relapse of Clostridium difficile associated diarrhoea: a randomized, controlled study. Clin Gastroenterol Hepatol 2005; 3:442-448.
70. Lewis S, Burmeister S, Cohen S, Brazier J, Awathi A. Failure of dietary oligofructose to prevent antibiotic-associated diarrhoea. Alim Pharm Ther 2005; 21:469-477.
71. Brunser O, Gotteland M, Cruchet S, Figueroa G, Garrido D, Steenhout P. Effect of milk formula with prebiotics on the intestinal microbiota of infants after an antibiotic treatment. Pediatr Res 2006; 59:451-456.
72. Vrese M, Marteau P. Probiotics and prebiotics: effects on diarrhea. J Nutr 2007; 137:S803-S811.
73. Cummings JH, Christie S, Cole TJ. A study of fructo-oligosac-charides in the prevention of travellers' diarrhoea. Alimen Pharmacol Ther 2001; 8: 1139-1145.
74. Haarman M, Knol J. Quantitative real-time PCR analysis of fecal Lactobacillus species in infants receiving a prebiotic infant formula. Appl Environ Microbiol 2006; 72:2359-65.
75. Knol J, Boehm G, Lidestri M, Negretti F, Jelinek J, Agosti M, et al. Increase of faecal bifidobacteria due to dietary oligosac-charides induces a reduction of clinically relevant pathogen germs in the faeces of formula-fed preterm infants. Acta Paediatr 2005; 94:S31-S33.
76. Knol J, Scholtens P, Kafka C, Wells J. Colon microflora in infants fed formula with galacto- and fructo-oligosaccharides: more like breast-fed infants. J Pediatr Gastroenterol Nutr 2005; 40:36-42.
77. Moro G, Minoli I, Mosca M, Fanaro S, Jelinek J, Stahl, B. et al. Dosage-related bifidogenic effects of galacto- and fructooligosaccharides in formula-fed term infants. J Pediatric Gastroenterol Nutr 2002; 34:291-295.
78. ESPGHAN Committee on Nutrition. Prebiotic oligosaccha-rides in dietetic products for infants: a commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr 2004; 39:465-473.
79. Bakker-Zierikzee AM, Tol E, Kroes H, Alles MS, Kok FJ, Bindels JG. 2006. Faecal SIgA secretion in infants fed on prebiotic infant formula. Pediatr Allergy Immunol 2006; 17:134-140.
80. Moore N, Chão C, Yang LP, Storm H, Oliva-Hemker M, Saavedra JM. Effects of fructo-oligosaccharide-supplemented infant cereal: a doubleblind, randomized trial. British J Nutr 2003; 90:581-587.
81. Oli MW, Petschow BW, Buddington RK. Evaluation of fructooligosaccharide supplementation of oral electrolyte solutions for treatment of diarrhoea (recovery of the intestinal bacteria). Dig Dis Sci 1998; 43:138-47.
82. Francavilla R, Castellaneta S Masciale A, Straziuso S, Polimeno L, Gagliardi F, Boehm G, Miniello V. Intestinal permeability and faecal flora of infants fed with prebiotic supplemented formula: a double blind placebo controlled study. J Pediatric Gastroenterol Nutr 2006; 42:PN2-PN21.
83. Mihatsch WA, Hoegel J, Pohlandt F. Prebiotic oligosaccharides reduce stool viscosity and accelerate gastrointestinal transport in preterm infants. Acta Paediatr 2006; 95:843-848.
84. Schmelzle H, Wirth S, Skopnik H, Radke M, Knol J, et al. Randomized double-blind study of the nutritional efficacy and bifidogenicity of a new infant formula containing partially hy-drolyzed protein, a high beta-palmitic acid level, and nondigestible oligosaccharides. J Pediatr Gastroenterol Nutr 2003; 36:343-351.
85. Waligora-Dupriet AJ, Campeotto F, Nicolis I, Bonet A, Soulaines P, Dupont C, et al. Effect of oligofructose supplementation on gut microflora and well-being in young children attending a day care centre. Int J Food Microbiol 2007; 113:108-113.
86. Duggan C, Penny ME, Hibberd P, Gil A, Huapaya A, Cooper A, et al. Oligofructose-supplemented infant cereal: 2 randomized, blinded, community-based trials in Peruvian infants. Am J Clin Nutr 2003; 77: 937-942.
87. Saavedra J.M, Tschernia A. Human studies with probiotics and prebiotics: clinical implications. British J Nutr 2002; 87:S241-S246.
88. Shoaf K, Mulvey JL, Armstrong GL, Hutkins RW. Prebiotic galactooligosaccharides reduce adherence of enteropathogenic Escherichia coli to tissue culture cells. Infec Immun 2006; 74:6920-6928.
89. Sharon N, Lis H. The structural basis for carbohydrate recognition by lectins. Adv Exp Med Biol 2001; 491:1-16.
90. Ofek I, Hasty DL, Sharon N. Anti-adhesion therapy of bacterial diseases: prospects and problems. FEMS Immunol Med Microbiol 2003;38(3):181-191.
91. Fooks L, Gibson GR. In Vitro investigations of the effect of probiotics and prebiotics on selected human intestinal pathogens. FEMS Microbiol Ecology 2002; 1:67-75.
92. Usera MA, Rodriguez A, Echeita A, Cano R. Multiple analysis of a foodborne outbreak caused by infant formula contaminated by an atypical Salmonella virchow strain. Eur J Clin Microbiol Infect Dis 1998; 17(8):551-555.
93. O'Brien S, Healy B, Negredo C, Anderson W, Fanning S, Iversen C. Prevalence of Cronobacter species (Enterobacter sakazakii) in follow-on infant formulae and infant drinks. Lett Appl Microbiol. 2009; 48(5):536-541.
94. Fiore A, Casale M, Aureli P. Enterobacter sakazakii: epidemiology, clinical presentation, prevention and control. Ann Ist Super Sanita 2008; 44(3):275-280.
95. Hunter CJ, Petrosyan M, Ford HR, Prasadarao NV. Enterobacter sakazakii: an emerging pathogen in infants and neonates. Surg Infect (Larchmt) 2008; 9(5):533-539.
96. O'Brien S, Healy B, Negredo C, Anderson W, Fanning S, Iversen C. Prevalence of Cronobacter species (Enterobacter sakazakii) in follow-on infant formulae and infant drinks. Lett Appl Microbiol. 2009; 48(5):536-541.
97. Cahill SM, Wachsmuth IK, Costarrica Mde L, Ben Embarek PK. Powdered infant formula as a source of Salmonella infection in infants. Clin Infect Dis. 2008 Jan 15; 46(2):268-273.
98. Jones TF, Ingram LA, Fullerton KE, Marcus R, Anderson BJ, McCarthy PV, et al. A case-control study of the epidemiology of sporadic Salmonella infection in infants. Pediatrics. 2006; 118(6):2380-2387.
99. Lai KK. Enterobacter sakazakii infections among neonates, infants, children, and adults. Medicine 2001;80: 113-122.